{"id":347059,"date":"2025-08-25T11:11:21","date_gmt":"2025-08-25T11:11:21","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-arrowhead-pharmaceuticals\/"},"modified":"2025-08-25T11:11:21","modified_gmt":"2025-08-25T11:11:21","slug":"how-to-buy-arrowhead-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/","title":{"rendered":"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-347059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Arrowhead Pharmaceuticals (ARWR) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin; mevcut fiyat analizi, risk de\u011ferlendirmesi ve 2025 f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci dahil.","description_source":{"label":"Description","type":"textarea","formatted_value":"Arrowhead Pharmaceuticals (ARWR) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin; mevcut fiyat analizi, risk de\u011ferlendirmesi ve 2025 f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci dahil."},"intro":"Keskin genetik t\u0131pta yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Arrowhead Pharmaceuticals, hastal\u0131klar\u0131 genetik k\u00f6klerinde hedef alan devrim niteli\u011findeki RNAi teknolojisi ile sa\u011fl\u0131k hizmetlerinin gelece\u011fini temsil ediyor. Bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014kalp hastal\u0131klar\u0131ndan nadir genetik bozukluklara kadar her \u015feyi tedavi etme \u015feklimizi d\u00f6n\u00fc\u015ft\u00fcrebilecek t\u0131bbi inovasyonun bir par\u00e7as\u0131na sahip olma \u015fans\u0131d\u0131r. ARWR'nin neden dikkatinizi hak etti\u011fini ve bu heyecan verici yolculu\u011fun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin genetik t\u0131pta yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Arrowhead Pharmaceuticals, hastal\u0131klar\u0131 genetik k\u00f6klerinde hedef alan devrim niteli\u011findeki RNAi teknolojisi ile sa\u011fl\u0131k hizmetlerinin gelece\u011fini temsil ediyor. Bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014kalp hastal\u0131klar\u0131ndan nadir genetik bozukluklara kadar her \u015feyi tedavi etme \u015feklimizi d\u00f6n\u00fc\u015ft\u00fcrebilecek t\u0131bbi inovasyonun bir par\u00e7as\u0131na sahip olma \u015fans\u0131d\u0131r. ARWR'nin neden dikkatinizi hak etti\u011fini ve bu heyecan verici yolculu\u011fun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Mevcut Piyasa Konumu ve Fiyat Analizi<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Arrowhead Pharmaceuticals (ARWR) hisseleri <strong>19,99 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin yolculu\u011funda ilgin\u00e7 bir an\u0131 temsil ediyor\u201452 haftal\u0131k en d\u00fc\u015f\u00fck seviyesi olan 9,57 $'\u0131n olduk\u00e7a \u00fczerinde ama y\u0131ll\u0131k en y\u00fcksek seviyesi olan 27,34 $'\u0131n %28 alt\u0131nda.<\/p> <p><strong>Takviminize not edin: 25 Kas\u0131m 2025<\/strong> bir sonraki kritik tarihiniz. Arrowhead'in bir sonraki kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu. Tarihsel olarak, bu t\u00fcr olaylar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 ARWR Hisselerini Nas\u0131l Etkiler?<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>7 A\u011fu 2025<\/td><td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>18,50 $<\/td><td>-%8,1 (EPS hedefi ka\u00e7\u0131r\u0131ld\u0131)<\/td><\/tr> <tr><td>12 May 2025<\/td><td>2. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>16,80 $<\/td><td>+%6,5 (pipeline ilerlemesi)<\/td><\/tr> <tr><td>\u015eub 2025<\/td><td>1. \u00c7eyrek Raporu<\/td><td>14,20 $<\/td><td>+%12,3 (Sarepta anla\u015fma haberi)<\/td><\/tr> <tr><td>Kas 2024<\/td><td>\u00d6nceki 3. \u00c7eyrek<\/td><td>15,75 $<\/td><td>-%4,2 (klinik gecikmeler)<\/td><\/tr> <\/tbody> <\/table> <p>Model, olumlu klinik deneme haberlerinin genellikle kazan\u00e7 sonu\u00e7lar\u0131ndan daha b\u00fcy\u00fck kazan\u00e7lar sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6steriyor\u2014yat\u0131r\u0131m zamanlamas\u0131 i\u00e7in \u00f6nemli bir i\u00e7g\u00f6r\u00fc.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2> <p>Arrowhead, herhangi bir yat\u0131r\u0131mc\u0131n\u0131n kalbini h\u0131zland\u0131racak bir h\u0131z treni yolculu\u011funda oldu. Son alt\u0131 ayda, ARWR \u015eubat diplerinden <strong>%65 etkileyici getiri<\/strong> sa\u011flad\u0131:<\/p> <p><strong>\u015eubat 2025<\/strong>: 12,10 $ (kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015f)<br\/> <strong>Mart 2025<\/strong>: 13,85 $ (kademeli toparlanma ba\u015flad\u0131)<br\/> <strong>Nisan 2025<\/strong>: 15,20 $ (pipeline iyimserli\u011fi artt\u0131)<br\/> <strong>May\u0131s 2025<\/strong>: 17,90 $ (2. \u00e7eyrek sonu\u00e7lar\u0131 art\u0131\u015f\u0131)<br\/> <strong>Haziran 2025<\/strong>: 16,50 $ (sekt\u00f6r genelinde biyotek geri \u00e7ekilmesi)<br\/> <strong>Temmuz 2025<\/strong>: 18,75 $ (klinik deneme ilerlemesi)<br\/> <strong>A\u011fustos 2025<\/strong>: 19,99 $ (mevcut konsolidasyon)<\/p> <p>Bu etkileyici y\u00fckseli\u015fin arkas\u0131ndaki itici g\u00fc\u00e7ler \u015funlard\u0131r:<\/p> <ul> <li>Ba\u015far\u0131l\u0131 Faz 3 kay\u0131t tamamlamalar\u0131<\/li> <li>Sarepta Therapeutics'ten 100 milyon dolarl\u0131k kilometre ta\u015f\u0131 \u00f6demesi<\/li> <li>FDA'n\u0131n ilk Yeni \u0130la\u00e7 Ba\u015fvurusunu kabul etmesi<\/li> <li>Stratejik ortakl\u0131k duyurular\u0131<\/li> <\/ul>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve pipeline geli\u015fmelerine dayanarak, gelecekte neler olabilece\u011fi:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 24-28 $ (y\u00fczde 20-40 art\u0131\u015f)<br\/> <em>Kataliz\u00f6r: Kas\u0131m FDA karar\u0131 plozasiran i\u00e7in<\/em><\/p> <p><strong>2026 Projeksiyonu<\/strong>: 32-38 $ (y\u00fczde 60-90 b\u00fcy\u00fcme potansiyeli)<br\/> <em>\u0130tici G\u00fc\u00e7: Olas\u0131 ticari lansman ve geni\u015fleyen ortakl\u0131klar<\/em><\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 45-55 $ (y\u00fczde 125-175 de\u011fer art\u0131\u015f\u0131)<br\/> <em>Temel: Birden fazla onaylanm\u0131\u015f terapi ve gelir \u00e7e\u015fitlendirmesi<\/em><\/p> <p><strong>2030 Vizyonu<\/strong>: 65-80 $ (y\u00fczde 225-300 uzun vadeli kazan\u00e7)<br\/> <em>Vizyon: S\u00fcrd\u00fcr\u00fclebilir k\u00e2rl\u0131l\u0131kla RNAi terapi lideri olarak konumlanma<\/em><\/p> <p><strong>Karar<\/strong>: Biyotek volatilitesini tolere edebilen uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM.<\/p>  <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken B\u00fcy\u00fck Riskler<\/h3> <p><strong>FDA Onay Belirsizli\u011fi<\/strong>: 18 Kas\u0131m 2025 PDUFA tarihi plozasiran i\u00e7in ikili bir olayd\u0131r\u2014onay hisseleri y\u00fckseltebilir, reddedilme ise %30-50 d\u00fc\u015f\u00fc\u015fe neden olabilir.<\/p> <p><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: D\u00f6rt Faz 3 \u00e7al\u0131\u015fmas\u0131 devam ederken, olumsuz herhangi bir veri de\u011ferlemeyi \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir. Biyotek hisseleri genellikle mevcut kazan\u00e7lardan \u00e7ok umut \u00fczerine i\u015flem g\u00f6r\u00fcr.<\/p> <p><strong>Nakit Yakma Endi\u015feleri<\/strong>: \"2028'e kadar finanse edilmi\u015f\" olsa da, \u015firketin negatif k\u00e2r marj\u0131 (-%25,9) denemeler beklenenden uzun s\u00fcrerse ek finansman gerektirebilir.<\/p> <p><strong>Sekt\u00f6r Volatilitesi<\/strong>: A\u011fustos 2025'te g\u00f6r\u00fcld\u00fc\u011f\u00fc gibi, ARWR tek bir g\u00fcnde sekt\u00f6r genelindeki endi\u015feler veya rakip haberleri nedeniyle %10 d\u00fc\u015febilir.<\/p> <h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3> <ul> <li><strong>D\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc Ortakl\u0131klar<\/strong>: Sarepta Therapeutics i\u015f birli\u011fi potansiyel olarak 1 milyar dolardan fazla kilometre ta\u015f\u0131 de\u011ferinde olabilir.<\/li> <li><strong>Pipeline \u0130lerlemesi<\/strong>: Faz 3 \u00e7al\u0131\u015fmalar\u0131nda d\u00f6rt aday, tek bir ilaca ba\u011fl\u0131 kalmadan birden fazla \u015fans yarat\u0131yor.<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: RNAi teknolojisi, kan\u0131tlanm\u0131\u015f ticari ba\u015far\u0131 hikayeleriyle ana ak\u0131m kabul g\u00f6r\u00fcyor.<\/li> <li><strong>Mali \u0130stikrar<\/strong>: A\u011fustos 2025'te 50 milyon dolarl\u0131k hisse geri al\u0131m\u0131, y\u00f6netimin g\u00fcvenini g\u00f6steriyor.<\/li> <\/ul>  <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p><strong>Ciddi \u00d6neriler:<\/strong><\/p> <ol> <li><strong>Ortalama Maliyetle Yat\u0131r\u0131m<\/strong>: M\u00fckemmel giri\u015f zaman\u0131n\u0131 yakalamaya \u00e7al\u0131\u015fmak yerine ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>Kazan\u00e7 Sonras\u0131 D\u00fc\u015f\u00fc\u015fleri Bekleyin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131, hisse geri \u00e7ekilirse al\u0131m f\u0131rsat\u0131 yaratabilir<\/li> <li><strong>Ak\u0131ll\u0131ca Tahsis Edin<\/strong>: Volatilite nedeniyle biyotek pozisyonunuzu toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'u ile s\u0131n\u0131rlay\u0131n<\/li> <\/ol> <p><strong>Esprili Tecr\u00fcbeli Bilgisi<\/strong>: \"ARWR ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014son derece heyecan verici ama dramatik ruh hali de\u011fi\u015fimlerine a\u00e7\u0131kt\u0131r. Duygusal dalgalanmalara dayanabiliyorsan\u0131z \u00e7iftli\u011fi riske atmay\u0131n!\"<\/p>  <h2>\u2705 Arrowhead Pharmaceuticals (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeleri ve kesirli hisse sunan bir platform se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"ARWR\" Aray\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>\u00dccretleri ve sipari\u015f detaylar\u0131n\u0131 iki kez kontrol edin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131?<\/h2> <p>\u00d6nemli sermayeyi taahh\u00fct etmeden \u00f6nce denemek isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile piyasa dinamiklerini \u00f6\u011frenmeye ve pratik yapmaya ba\u015flayabilirsiniz<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: KYC s\u00fcreci herhangi bir resmi kimlikle dakikalar i\u00e7inde tamamlan\u0131r<\/li> <li><strong>Esnek Para \u00c7ekme<\/strong>: Kripto paralar dahil 100'den fazla \u00f6deme y\u00f6ntemi<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: S\u00fcrekli \u00f6\u011frenim i\u00e7in <a href=\"\/blog\">Pocket Option bloguna<\/a> eri\u015fim<\/li> <\/ul> <p>Bu yakla\u015f\u0131m, biyotek yat\u0131r\u0131m dinamiklerini \u00f6\u011frenirken daha k\u00fc\u00e7\u00fck pozisyonlarla deneyim kazanman\u0131z\u0131 sa\u011flar.<\/p>  <h2>\ud83e\uddec 2025'te Arrowhead: Genetik T\u0131pta \u00d6nc\u00fc<\/h2> <p>Arrowhead Pharmaceuticals, RNA giri\u015fimi teknolojisiyle t\u0131bbi inovasyonun \u00f6n saflar\u0131nda yer al\u0131yor. Belirtileri y\u00f6neten geleneksel ila\u00e7lar\u0131n aksine, Arrowhead'in tedavileri hastal\u0131klar\u0131 genetik kayna\u011f\u0131nda hedef al\u0131r\u2014hastal\u0131\u011fa neden olan genleri kelimenin tam anlam\u0131yla susturur.<\/p> <p>\u015eirketin \"20 in 25\" vizyonu, y\u0131l sonuna kadar klinik denemelerde veya piyasada 20 ila\u00e7 bulundurmay\u0131 hedefliyor ve bu inan\u0131lmaz bir h\u0131rs\u0131 g\u00f6steriyor. Sarepta'dan al\u0131nan son 100 milyon dolarl\u0131k kilometre ta\u015f\u0131 \u00f6demesi ve ba\u015far\u0131l\u0131 Faz 3 kay\u0131tlar\u0131, bu vaatlerin yerine getirildi\u011fini g\u00f6steriyor.<\/p> <p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025'te Arrowhead bilim insanlar\u0131, RNAi teknolojilerinin daha \u00f6nce \"ila\u00e7 geli\u015ftirilemez\" olarak kabul edilen beyin, kemik ve hatta g\u00f6z gibi dokulara ula\u015ft\u0131r\u0131labilece\u011fini ke\u015ffettiler\u2014be\u015f y\u0131l \u00f6ncesine kadar imkans\u0131z say\u0131lan tedavi olanaklar\u0131n\u0131 a\u00e7\u0131yor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Mevcut Piyasa Konumu ve Fiyat Analizi<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Arrowhead Pharmaceuticals (ARWR) hisseleri <strong>19,99 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin yolculu\u011funda ilgin\u00e7 bir an\u0131 temsil ediyor\u201452 haftal\u0131k en d\u00fc\u015f\u00fck seviyesi olan 9,57 $&#8217;\u0131n olduk\u00e7a \u00fczerinde ama y\u0131ll\u0131k en y\u00fcksek seviyesi olan 27,34 $&#8217;\u0131n %28 alt\u0131nda.<\/p>\n<p><strong>Takviminize not edin: 25 Kas\u0131m 2025<\/strong> bir sonraki kritik tarihiniz. Arrowhead&#8217;in bir sonraki kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu. Tarihsel olarak, bu t\u00fcr olaylar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 ARWR Hisselerini Nas\u0131l Etkiler?<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fu 2025<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>18,50 $<\/td>\n<td>-%8,1 (EPS hedefi ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<\/tr>\n<tr>\n<td>12 May 2025<\/td>\n<td>2. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>16,80 $<\/td>\n<td>+%6,5 (pipeline ilerlemesi)<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>1. \u00c7eyrek Raporu<\/td>\n<td>14,20 $<\/td>\n<td>+%12,3 (Sarepta anla\u015fma haberi)<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>\u00d6nceki 3. \u00c7eyrek<\/td>\n<td>15,75 $<\/td>\n<td>-%4,2 (klinik gecikmeler)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Model, olumlu klinik deneme haberlerinin genellikle kazan\u00e7 sonu\u00e7lar\u0131ndan daha b\u00fcy\u00fck kazan\u00e7lar sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6steriyor\u2014yat\u0131r\u0131m zamanlamas\u0131 i\u00e7in \u00f6nemli bir i\u00e7g\u00f6r\u00fc.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2>\n<p>Arrowhead, herhangi bir yat\u0131r\u0131mc\u0131n\u0131n kalbini h\u0131zland\u0131racak bir h\u0131z treni yolculu\u011funda oldu. Son alt\u0131 ayda, ARWR \u015eubat diplerinden <strong>%65 etkileyici getiri<\/strong> sa\u011flad\u0131:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: 12,10 $ (kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015f)<br \/> <strong>Mart 2025<\/strong>: 13,85 $ (kademeli toparlanma ba\u015flad\u0131)<br \/> <strong>Nisan 2025<\/strong>: 15,20 $ (pipeline iyimserli\u011fi artt\u0131)<br \/> <strong>May\u0131s 2025<\/strong>: 17,90 $ (2. \u00e7eyrek sonu\u00e7lar\u0131 art\u0131\u015f\u0131)<br \/> <strong>Haziran 2025<\/strong>: 16,50 $ (sekt\u00f6r genelinde biyotek geri \u00e7ekilmesi)<br \/> <strong>Temmuz 2025<\/strong>: 18,75 $ (klinik deneme ilerlemesi)<br \/> <strong>A\u011fustos 2025<\/strong>: 19,99 $ (mevcut konsolidasyon)<\/p>\n<p>Bu etkileyici y\u00fckseli\u015fin arkas\u0131ndaki itici g\u00fc\u00e7ler \u015funlard\u0131r:<\/p>\n<ul>\n<li>Ba\u015far\u0131l\u0131 Faz 3 kay\u0131t tamamlamalar\u0131<\/li>\n<li>Sarepta Therapeutics&#8217;ten 100 milyon dolarl\u0131k kilometre ta\u015f\u0131 \u00f6demesi<\/li>\n<li>FDA&#8217;n\u0131n ilk Yeni \u0130la\u00e7 Ba\u015fvurusunu kabul etmesi<\/li>\n<li>Stratejik ortakl\u0131k duyurular\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve pipeline geli\u015fmelerine dayanarak, gelecekte neler olabilece\u011fi:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 24-28 $ (y\u00fczde 20-40 art\u0131\u015f)<br \/> <em>Kataliz\u00f6r: Kas\u0131m FDA karar\u0131 plozasiran i\u00e7in<\/em><\/p>\n<p><strong>2026 Projeksiyonu<\/strong>: 32-38 $ (y\u00fczde 60-90 b\u00fcy\u00fcme potansiyeli)<br \/> <em>\u0130tici G\u00fc\u00e7: Olas\u0131 ticari lansman ve geni\u015fleyen ortakl\u0131klar<\/em><\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 45-55 $ (y\u00fczde 125-175 de\u011fer art\u0131\u015f\u0131)<br \/> <em>Temel: Birden fazla onaylanm\u0131\u015f terapi ve gelir \u00e7e\u015fitlendirmesi<\/em><\/p>\n<p><strong>2030 Vizyonu<\/strong>: 65-80 $ (y\u00fczde 225-300 uzun vadeli kazan\u00e7)<br \/> <em>Vizyon: S\u00fcrd\u00fcr\u00fclebilir k\u00e2rl\u0131l\u0131kla RNAi terapi lideri olarak konumlanma<\/em><\/p>\n<p><strong>Karar<\/strong>: Biyotek volatilitesini tolere edebilen uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken B\u00fcy\u00fck Riskler<\/h3>\n<p><strong>FDA Onay Belirsizli\u011fi<\/strong>: 18 Kas\u0131m 2025 PDUFA tarihi plozasiran i\u00e7in ikili bir olayd\u0131r\u2014onay hisseleri y\u00fckseltebilir, reddedilme ise %30-50 d\u00fc\u015f\u00fc\u015fe neden olabilir.<\/p>\n<p><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: D\u00f6rt Faz 3 \u00e7al\u0131\u015fmas\u0131 devam ederken, olumsuz herhangi bir veri de\u011ferlemeyi \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir. Biyotek hisseleri genellikle mevcut kazan\u00e7lardan \u00e7ok umut \u00fczerine i\u015flem g\u00f6r\u00fcr.<\/p>\n<p><strong>Nakit Yakma Endi\u015feleri<\/strong>: &#8220;2028&#8217;e kadar finanse edilmi\u015f&#8221; olsa da, \u015firketin negatif k\u00e2r marj\u0131 (-%25,9) denemeler beklenenden uzun s\u00fcrerse ek finansman gerektirebilir.<\/p>\n<p><strong>Sekt\u00f6r Volatilitesi<\/strong>: A\u011fustos 2025&#8217;te g\u00f6r\u00fcld\u00fc\u011f\u00fc gibi, ARWR tek bir g\u00fcnde sekt\u00f6r genelindeki endi\u015feler veya rakip haberleri nedeniyle %10 d\u00fc\u015febilir.<\/p>\n<h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3>\n<ul>\n<li><strong>D\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc Ortakl\u0131klar<\/strong>: Sarepta Therapeutics i\u015f birli\u011fi potansiyel olarak 1 milyar dolardan fazla kilometre ta\u015f\u0131 de\u011ferinde olabilir.<\/li>\n<li><strong>Pipeline \u0130lerlemesi<\/strong>: Faz 3 \u00e7al\u0131\u015fmalar\u0131nda d\u00f6rt aday, tek bir ilaca ba\u011fl\u0131 kalmadan birden fazla \u015fans yarat\u0131yor.<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: RNAi teknolojisi, kan\u0131tlanm\u0131\u015f ticari ba\u015far\u0131 hikayeleriyle ana ak\u0131m kabul g\u00f6r\u00fcyor.<\/li>\n<li><strong>Mali \u0130stikrar<\/strong>: A\u011fustos 2025&#8217;te 50 milyon dolarl\u0131k hisse geri al\u0131m\u0131, y\u00f6netimin g\u00fcvenini g\u00f6steriyor.<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p><strong>Ciddi \u00d6neriler:<\/strong><\/p>\n<ol>\n<li><strong>Ortalama Maliyetle Yat\u0131r\u0131m<\/strong>: M\u00fckemmel giri\u015f zaman\u0131n\u0131 yakalamaya \u00e7al\u0131\u015fmak yerine ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>Kazan\u00e7 Sonras\u0131 D\u00fc\u015f\u00fc\u015fleri Bekleyin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131, hisse geri \u00e7ekilirse al\u0131m f\u0131rsat\u0131 yaratabilir<\/li>\n<li><strong>Ak\u0131ll\u0131ca Tahsis Edin<\/strong>: Volatilite nedeniyle biyotek pozisyonunuzu toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10&#8217;u ile s\u0131n\u0131rlay\u0131n<\/li>\n<\/ol>\n<p><strong>Esprili Tecr\u00fcbeli Bilgisi<\/strong>: &#8220;ARWR ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014son derece heyecan verici ama dramatik ruh hali de\u011fi\u015fimlerine a\u00e7\u0131kt\u0131r. Duygusal dalgalanmalara dayanabiliyorsan\u0131z \u00e7iftli\u011fi riske atmay\u0131n!&#8221;<\/p>\n<h2>\u2705 Arrowhead Pharmaceuticals (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeleri ve kesirli hisse sunan bir platform se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;ARWR&#8221; Aray\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>\u00dccretleri ve sipari\u015f detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131?<\/h2>\n<p>\u00d6nemli sermayeyi taahh\u00fct etmeden \u00f6nce denemek isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile piyasa dinamiklerini \u00f6\u011frenmeye ve pratik yapmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: KYC s\u00fcreci herhangi bir resmi kimlikle dakikalar i\u00e7inde tamamlan\u0131r<\/li>\n<li><strong>Esnek Para \u00c7ekme<\/strong>: Kripto paralar dahil 100&#8217;den fazla \u00f6deme y\u00f6ntemi<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: S\u00fcrekli \u00f6\u011frenim i\u00e7in <a href=\"\/blog\">Pocket Option bloguna<\/a> eri\u015fim<\/li>\n<\/ul>\n<p>Bu yakla\u015f\u0131m, biyotek yat\u0131r\u0131m dinamiklerini \u00f6\u011frenirken daha k\u00fc\u00e7\u00fck pozisyonlarla deneyim kazanman\u0131z\u0131 sa\u011flar.<\/p>\n<h2>\ud83e\uddec 2025&#8217;te Arrowhead: Genetik T\u0131pta \u00d6nc\u00fc<\/h2>\n<p>Arrowhead Pharmaceuticals, RNA giri\u015fimi teknolojisiyle t\u0131bbi inovasyonun \u00f6n saflar\u0131nda yer al\u0131yor. Belirtileri y\u00f6neten geleneksel ila\u00e7lar\u0131n aksine, Arrowhead&#8217;in tedavileri hastal\u0131klar\u0131 genetik kayna\u011f\u0131nda hedef al\u0131r\u2014hastal\u0131\u011fa neden olan genleri kelimenin tam anlam\u0131yla susturur.<\/p>\n<p>\u015eirketin &#8220;20 in 25&#8221; vizyonu, y\u0131l sonuna kadar klinik denemelerde veya piyasada 20 ila\u00e7 bulundurmay\u0131 hedefliyor ve bu inan\u0131lmaz bir h\u0131rs\u0131 g\u00f6steriyor. Sarepta&#8217;dan al\u0131nan son 100 milyon dolarl\u0131k kilometre ta\u015f\u0131 \u00f6demesi ve ba\u015far\u0131l\u0131 Faz 3 kay\u0131tlar\u0131, bu vaatlerin yerine getirildi\u011fini g\u00f6steriyor.<\/p>\n<p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025&#8217;te Arrowhead bilim insanlar\u0131, RNAi teknolojilerinin daha \u00f6nce &#8220;ila\u00e7 geli\u015ftirilemez&#8221; olarak kabul edilen beyin, kemik ve hatta g\u00f6z gibi dokulara ula\u015ft\u0131r\u0131labilece\u011fini ke\u015ffettiler\u2014be\u015f y\u0131l \u00f6ncesine kadar imkans\u0131z say\u0131lan tedavi olanaklar\u0131n\u0131 a\u00e7\u0131yor!<\/p>\n"},"faq":[{"question":"Arrowhead Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, ARWR sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak sipari\u015f verin ve i\u015flemi onaylay\u0131n."},{"question":"ARWR hisselerinin riskleri nelerdir?","answer":"FDA onay belirsizli\u011fi, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, nakit yakma endi\u015feleri ve sekt\u00f6r volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"2025 i\u00e7in ARWR hisse fiyat\u0131 tahmini nedir?","answer":"2025 y\u0131l sonu hedefi 24-28 $ aras\u0131 olup %20-40 art\u0131\u015f potansiyeli ta\u015f\u0131maktad\u0131r."},{"question":"Yeni ba\u015flayanlar ARWR hisseleri i\u00e7in ne yapmal\u0131?","answer":"D\u00fczenli yat\u0131r\u0131m yapmal\u0131, kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015fleri beklemeli ve portf\u00f6y\u00fcn %5-10'unu biyotek hisselerine ay\u0131rmal\u0131d\u0131r."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, esnek para \u00e7ekme se\u00e7enekleri ve e\u011fitim kaynaklar\u0131 sunar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Arrowhead Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, ARWR sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak sipari\u015f verin ve i\u015flemi onaylay\u0131n."},{"question":"ARWR hisselerinin riskleri nelerdir?","answer":"FDA onay belirsizli\u011fi, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, nakit yakma endi\u015feleri ve sekt\u00f6r volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"2025 i\u00e7in ARWR hisse fiyat\u0131 tahmini nedir?","answer":"2025 y\u0131l sonu hedefi 24-28 $ aras\u0131 olup %20-40 art\u0131\u015f potansiyeli ta\u015f\u0131maktad\u0131r."},{"question":"Yeni ba\u015flayanlar ARWR hisseleri i\u00e7in ne yapmal\u0131?","answer":"D\u00fczenli yat\u0131r\u0131m yapmal\u0131, kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015fleri beklemeli ve portf\u00f6y\u00fcn %5-10'unu biyotek hisselerine ay\u0131rmal\u0131d\u0131r."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, esnek para \u00e7ekme se\u00e7enekleri ve e\u011fitim kaynaklar\u0131 sunar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T11:11:21+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T11:11:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/\",\"name\":\"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-25T11:11:21+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T11:11:21+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T11:11:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/","name":"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-25T11:11:21+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Arrowhead Pharmaceuticals, Inc. (ARWR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arrowhead Pharmaceuticals, Inc. (ARWR) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":347064,"slug":"how-to-buy-arrowhead-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Arrowhead Pharmaceuticals, Inc. (ARWR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Arrowhead Pharmaceuticals, Inc. (ARWR)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":347058,"slug":"how-to-buy-arrowhead-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Arrowhead Pharmaceuticals, Inc. (ARWR) - Investimento em a\u00e7\u00f5es da Arrowhead Pharmaceuticals, Inc. (ARWR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-arrowhead-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=347059"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347059\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=347059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=347059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=347059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}